Affiliations: [a] Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China | [b] Department of Dermatology, Henan Children’s Hospital, Zhengzhou, Henan, China
Correspondence:
[*]
Corresponding author: Xiubo Lu, Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, No. 1, Jian She Dong Road, Zhengzhou 450000, Henan, China. Tel.: +86 037167967241; Fax: +86 0371 67967241; E-mail: piuj7254336@163.com.
Note: [1] Co-first authors.
Abstract: BACKGROUNDS: The purpose of this study was to investigate clinical role and functional effects of miR-431 expression in papillary thyroid carcinoma (PTC). METHODS: Expression of miR-431 in PTC patient tissue samples and plasma samples was examined by using qRT-PCR methods. Cell migration and invasion capacity were evaluated using transwell assays. Western blot analysis was performed to detect protein expression after miR-431 overexpression in PTC cells. RESULTS: We demonstrated that miR-431 expression was lower in PTC tissues and plasma samples compared to their corresponding controls. MiR-431 expression was particularly lower in PTC patients with lymph node (LN) metastasis. In vitro, miR-431 overexpression significantly inhibited cell migration, invasion and EMT process by upregulating E-cadherin and downregulating Vimentin expression. Additionally, wedemonstrated that miR-431 overexpression suppressed Hedgehog (Hh) signaling pathway by downregulating Gli1 expression. CONCLUSION: Our results indicated that miR-431 could serve as a predictor for PTC patients with positive lymph node metastasis and a potential target of PTC treatment.
